Effect of Folate-Based Supplementation in Kidney Disease: A Systematic Review and Meta-analysis of Kidney, Cardiovascular, and Mortality Outcomes
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
CONTEXT: Hyperhomocysteinemia is common in patients with kidney disease and is potentially linked to increased cardiovascular risk. While folate-based supplementation effectively lowers homocysteine levels, its clinical benefits in kidney disease remain uncertain. OBJECTIVE: This systematic review and meta-analysis aimed to evaluate the effects of folate-based supplementation on homocysteine levels, kidney function, cardiovascular events, mortality, and safety in adult patients with acute kidney injury (AKI) or chronic kidney disease (CKD). DATA SOURCES: Following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, we searched PubMed, Embase, Web of Science, MEDLINE, CINAHL, and CENTRAL from database inception to March 24, 2024. DATA EXTRACTION: Randomized controlled trials (RCTs) and nonrandomized trials comparing folate-based supplementation with placebo, no intervention, or alternative folate formulations in adults with AKI or CKD were included. Two reviewers independently screened studies, performed full-text review, and extracted data. DATA ANALYSIS: A total of 37 studies with 8625 participants (35 RCTs, 2 non-RCTs) were included. All studies enrolled patients with CKD, and no eligible AKI studies were identified. Random-effects meta-analyses were conducted using mean differences (MDs) and risk ratios (RRs) with 95% CIs. Folate-based supplementation significantly lowered plasma homocysteine (14 RCTs; MD, -8.09 µmol/L; 95% CI, -11.54 to -4.63; I2 = 98%), with adverse events comparable to controls. However, no statistically significant reductions were observed in cardiovascular events (6 RCTs; RR, 0.88; 95% CI, 0.68-1.13; I2 = 13%), all-cause mortality (8 RCTs; RR, 1.02; 95% CI, 0.92-1.13; I2 = 0%), or cardiovascular mortality (7 RCTs; RR, 0.99; 95% CI, 0.75-1.29; I2 = 0%). Evidence for kidney function was limited; 2 RCTs reporting serum creatinine showed no significant effect (MD, -0.27 mg/dL; 95% CI, -1.29 to 0.74; I2 = 0%), whereas findings for long-term kidney disease progression were inconsistent. Subgroup and sensitivity analyses suggested more favorable point estimates among patients with end-stage kidney disease, higher folate dosages, alternative folate forms, shorter treatment durations, and lower baseline folate levels, but none reached statistical significance. CONCLUSIONS: Folate-based supplementation effectively lowers homocysteine in CKD but does not significantly reduce cardiovascular events or mortality, and there is insufficient evidence to support an effect on renal outcomes. Although a nonsignificant 12% relative reduction in cardiovascular events was observed, a trial of approximately 3174 participants would be required to adequately power detection of such an effect. Routine folate supplementation in CKD without another indication is therefore not supported by current evidence. The complete absence of eligible AKI studies highlights a critical research gap, and future adequately powered trials are warranted to clarify the role of folate in both CKD progression and AKI recovery. SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration No. [CRD42024589377].
Fields of Study & Subjects
Folate and B Vitamins Research
Dialysis and Renal Disease Management
Metabolism and Genetic Disorders
Publication details
- Journal / source
- Nutrition Reviews
- Publication date
- 26 March 2026
- Language
- EN